세계의 염증성 장질환 시장 : 산업 분석, 규모, 점유율, 성장, 동향, 예측(2024-2031년)

Persistence Market Research has recently published an in-depth report on the global Inflammatory Bowel Disease (IBD) Market, offering a detailed analysis of the key market dynamics. This comprehensive report delves into the drivers, trends, opportunities, and challenges shaping the IBD market, providing valuable insights into its structure and future growth trajectory.

Key Insights:

• Inflammatory Bowel Disease Market Size (2024E): US$22 Bn
• Projected Market Value (2031F): US$29.1 Bn
• Global Market Growth Rate (CAGR 2024 to 2031): 4.1%

Inflammatory Bowel Disease Market - Report Scope:

The Inflammatory Bowel Disease Market includes various treatment options and medications aimed at managing the symptoms and underlying causes of IBD, which encompasses conditions such as Crohn's disease and ulcerative colitis. These treatments range from anti-inflammatory drugs and immunosuppressants to biologics and surgery. The market serves a diverse patient population, including those with mild to severe symptoms, and spans multiple settings, such as hospitals, specialty clinics, and home care. The growth of the IBD market is driven by the increasing prevalence of the disease, advancements in therapeutic approaches, and the growing awareness and diagnosis of IBD across various demographics.

Market Growth Drivers:

Several key factors are driving the global Inflammatory Bowel Disease Market. The rising prevalence of IBD globally is a primary driver, with increasing awareness and better diagnostic tools leading to more diagnosed cases. Advances in treatment options, particularly the development of biologics and biosimilars, have significantly improved the quality of life for patients, thereby boosting market growth. Additionally, the growing investment in research and development (R&D) for novel therapies and the expansion of healthcare infrastructure in emerging markets are contributing to the market's expansion. The increasing focus on personalized medicine and the development of targeted therapies tailored to individual patients' needs also play a crucial role in driving market growth.

Market Restraints:

Despite the promising growth prospects, the Inflammatory Bowel Disease Market faces several challenges. The high cost of biologic therapies and the long-term treatment required for chronic conditions like IBD can be significant barriers to market growth, particularly in regions with limited healthcare funding or insurance coverage. Additionally, the side effects associated with some IBD treatments, including immunosuppressants and corticosteroids, may deter patients from adhering to prescribed therapies. Furthermore, the market faces competition from alternative treatments, such as dietary modifications and holistic approaches, which some patients prefer due to concerns about the long-term use of pharmaceuticals. These challenges highlight the need for ongoing R&D to develop more effective and safer treatment options.

Market Opportunities:

The IBD market presents significant opportunities for growth, particularly with the development of novel therapies and the increasing adoption of biosimilars. The growing interest in personalized medicine offers opportunities for companies to develop targeted therapies that cater to specific patient subgroups, potentially improving treatment outcomes and reducing side effects. Additionally, the expansion of telemedicine and digital health platforms provides new channels for patient management and follow-up, improving access to care, especially in remote areas. The market also has potential for growth through the increasing focus on lifestyle modifications and preventive care, which could complement traditional treatment options. Strategic partnerships and collaborations between pharmaceutical companies, research institutions, and healthcare providers are essential for capitalizing on these opportunities and maintaining a competitive edge in the market.

Key Questions Answered in the Report:

• What are the primary factors driving the growth of the Inflammatory Bowel Disease Market globally?
• Which treatment options are leading the adoption in various patient settings?
• How are technological advancements influencing the competitive landscape of the IBD Market?
• Who are the key players in the IBD Market, and what strategies are they employing to stay competitive?
• What are the emerging trends and future prospects in the global Inflammatory Bowel Disease Market?

Competitive Intelligence and Business Strategy:

Leading players in the global Inflammatory Bowel Disease Market, including AbbVie Inc., Johnson & Johnson, and Pfizer Inc., focus on innovation, product differentiation, and strategic collaborations to gain a competitive edge. These companies invest heavily in R&D to develop advanced therapies for IBD, including biologics and biosimilars, and explore new treatment modalities such as gene therapy. Collaborations with research institutions and healthcare providers facilitate the development of novel therapies and promote their adoption in clinical practice. Emphasis on patient education, high-quality products, and comprehensive marketing strategies fosters market growth and enhances brand loyalty in the evolving IBD Market landscape.

Key Companies Profiled:

• AbbVie Inc.
• Janssen Biotech, Inc.
• Pfizer Inc.
• Takeda Pharmaceutical Company Limited
• Ferring Pharmaceuticals
• Amgen Inc.
• Eli Lilly and Company
• Novartis AG
• Bristol-Myers Squibb
• Johnson & Johnson
• Merck & Co., Inc.
• GlaxoSmithKline plc

Inflammatory Bowel Disease Market Industry Segmentation

By Disease Type

• Crohn's Disease
• Ulcerative Colitis

By Drug Class

• Aminosalicylates
• Corticosteroids
• Immunomodulators
• Others

By Distribution Channel

• Hospital Pharmacies
• Retail Pharmacies
• E-Commerce Platforms
• Others

By Region

• North America
• Europe
• Asia-Pacific
• The Middle East and Africa
• Latin America

Table of Contents

1. Executive Summary

• 1.1. Global Inflammatory Bowel Disease Market Snapshot, 2024-2031
• 1.2. Market Opportunity Assessment, 2024-2031, US$ Bn
• 1.3. Key Market Trends
• 1.4. Future Market Projections
• 1.5. Premium Market Insights
• 1.6. Industry Developments and Key Market Events
• 1.7. PMR Analysis and Recommendations

2. Market Overview

• 2.1. Market Scope and Definition
• 2.2. Market Dynamics
  • 2.2.1. Drivers
  • 2.2.2. Restraints
  • 2.2.3. Opportunity
  • 2.2.4. Challenges
  • 2.2.5. Key Trends
• 2.3. Macro-Economic Factors
  • 2.3.1. Global Sectorial Outlook
  • 2.3.2. Global GDP Growth Outlook
  • 2.3.3. Global Healthcare Spending Outlook
• 2.4. COVID-19 Impact Analysis
• 2.5. Forecast Factors - Relevance and Impact

3. Value Added Insights

• 3.1. Technology Assessment
• 3.2. Regulatory Landscape
• 3.3. Value Chain Analysis
• 3.4. Key Deals and Mergers
• 3.5. PESTLE Analysis
• 3.6. Porter's Five Force Analysis
• 3.7. Regional Prices and Disease Type Preferences

4. Global Inflammatory Bowel Disease Market Outlook: Historical (2019-2023) and Forecast (2024-2031)

• 4.1. Key Highlights
  • 4.1.1. Market Size (US$ Bn) and Y-o-Y Growth
  • 4.1.2. Absolute $ Opportunity
• 4.2. Market Size (US$ Bn) Analysis and Forecast
  • 4.2.1. Historical Market Size (US$ Bn) Analysis, 2019-2023
  • 4.2.2. Current Market Size (US$ Bn) Analysis and Forecast, 2023-2031
• 4.3. Global Inflammatory Bowel Disease Market Outlook: Disease Type
  • 4.3.1. Introduction / Key Findings
  • 4.3.2. Historical Market Size (US$ Bn) Analysis, By Disease Type, 2019-2023
  • 4.3.3. Current Market Size (US$ Bn) Analysis and Forecast, By Disease Type, 2024-2031
    • 4.3.3.1. Crohn's Disease
    • 4.3.3.2. Ulcerative Colitis
• 4.4. Market Attractiveness Analysis: Disease Type
• 4.5. Global Inflammatory Bowel Disease Market Outlook: Drug Class
  • 4.5.1. Introduction / Key Findings
  • 4.5.2. Historical Market Size (US$ Bn) Analysis, By Drug Class, 2019-2023
  • 4.5.3. Current Market Size (US$ Bn) Analysis and Forecast, By Drug Class, 2024-2031
    • 4.5.3.1. Aminosalicylates
    • 4.5.3.2. Corticosteroids
    • 4.5.3.3. Immunomodulators
    • 4.5.3.4. Others
• 4.6. Market Attractiveness Analysis: Drug Class
• 4.7. Global Inflammatory Bowel Disease Market Outlook: Distribution Channel
  • 4.7.1. Introduction / Key Findings
  • 4.7.2. Historical Market Size (US$ Bn) Analysis, By Distribution Channel, 2019-2023
  • 4.7.3. Current Market Size (US$ Bn) Analysis and Forecast, By Distribution Channel, 2024-2031
    • 4.7.3.1. Hospital Pharmacies
    • 4.7.3.2. Retail Pharmacies
    • 4.7.3.3. E-Commerce Platforms
    • 4.7.3.4. Others
• 4.8. Market Attractiveness Analysis: Distribution Channel

5. Global Inflammatory Bowel Disease Market Outlook: Region

• 5.1. Key Highlights
• 5.2. Historical Market Size (US$ Bn) Analysis, By Region, 2019-2023
• 5.3. Current Market Size (US$ Bn) Analysis and Forecast, By Region, 2024-2031
  • 5.3.1. North America
  • 5.3.2. Europe
  • 5.3.3. East Asia
  • 5.3.4. South Asia and Oceania
  • 5.3.5. Latin America
  • 5.3.6. Middle East & Africa
• 5.4. Market Attractiveness Analysis: Region

6. North America Inflammatory Bowel Disease Market Outlook: Historical (2019-2023) and Forecast (2024-2031)

• 6.1. Key Highlights
• 6.2. Pricing Analysis
• 6.3. Historical Market Size (US$ Bn) Analysis, By Market, 2019-2023
  • 6.3.1. By Country
  • 6.3.2. By Disease Type
  • 6.3.3. By Drug Class
  • 6.3.4. By Distribution Channel
• 6.4. Current Market Size (US$ Bn) Analysis and Forecast, By Country, 2024-2031
  • 6.4.1. U.S.
  • 6.4.2. Canada
• 6.5. Current Market Size (US$ Bn) Analysis and Forecast, By Disease Type, 2024-2031
  • 6.5.1. Crohn's Disease
  • 6.5.2. Ulcerative Colitis
• 6.6. Current Market Size (US$ Bn) Analysis and Forecast, By Drug Class, 2024-2031
  • 6.6.1. Aminosalicylates
  • 6.6.2. Corticosteroids
  • 6.6.3. Immunomodulators
  • 6.6.4. Others
• 6.7. Current Market Size (US$ Bn) Analysis and Forecast, By Distribution Channel, 2024-2031
  • 6.7.1. Hospital Pharmacies
  • 6.7.2. Retail Pharmacies
  • 6.7.3. E-Commerce Platforms
  • 6.7.4. Others
• 6.8. Market Attractiveness Analysis

7. Europe Inflammatory Bowel Disease Market Outlook: Historical (2019-2023) and Forecast (2024-2031)

• 7.1. Key Highlights
• 7.2. Pricing Analysis
• 7.3. Historical Market Size (US$ Bn) Analysis, By Market, 2019-2023
  • 7.3.1. By Country
  • 7.3.2. By Disease Type
  • 7.3.3. By Drug Class
  • 7.3.4. By Distribution Channel
• 7.4. Current Market Size (US$ Bn) Analysis and Forecast, By Country, 2024-2031
  • 7.4.1. Germany
  • 7.4.2. France
  • 7.4.3. U.K.
  • 7.4.4. Italy
  • 7.4.5. Spain
  • 7.4.6. Russia
  • 7.4.7. Turkey
  • 7.4.8. Rest of Europe
• 7.5. Current Market Size (US$ Bn) Analysis and Forecast, By Disease Type, 2024-2031
  • 7.5.1. Crohn's Disease
  • 7.5.2. Ulcerative Colitis
• 7.6. Current Market Size (US$ Bn) Analysis and Forecast, By Drug Class, 2024-2031
  • 7.6.1. Aminosalicylates
  • 7.6.2. Corticosteroids
  • 7.6.3. Immunomodulators
  • 7.6.4. Others
• 7.7. Current Market Size (US$ Bn) Analysis and Forecast, By Distribution Channel, 2024-2031
  • 7.7.1. Hospital Pharmacies
  • 7.7.2. Retail Pharmacies
  • 7.7.3. E-Commerce Platforms
  • 7.7.4. Others
• 7.8. Market Attractiveness Analysis

8. East Asia Inflammatory Bowel Disease Market Outlook: Historical (2019-2023) and Forecast (2024-2031)

• 8.1. Key Highlights
• 8.2. Pricing Analysis
• 8.3. Historical Market Size (US$ Bn) Analysis, By Market, 2019-2023
  • 8.3.1. By Country
  • 8.3.2. By Disease Type
  • 8.3.3. By Drug Class
  • 8.3.4. By Distribution Channel
• 8.4. Current Market Size (US$ Bn) Analysis and Forecast, By Country, 2024-2031
  • 8.4.1. China
  • 8.4.2. Japan
  • 8.4.3. South Korea
• 8.5. Current Market Size (US$ Bn) Analysis and Forecast, By Disease Type, 2024-2031
  • 8.5.1. Crohn's Disease
  • 8.5.2. Ulcerative Colitis
• 8.6. Current Market Size (US$ Bn) Analysis and Forecast, By Drug Class, 2024-2031
  • 8.6.1. Aminosalicylates
  • 8.6.2. Corticosteroids
  • 8.6.3. Immunomodulators
  • 8.6.4. Others
• 8.7. Current Market Size (US$ Bn) Analysis and Forecast, By Distribution Channel, 2024-2031
  • 8.7.1. Hospital Pharmacies
  • 8.7.2. Retail Pharmacies
  • 8.7.3. E-Commerce Platforms
  • 8.7.4. Others
• 8.8. Market Attractiveness Analysis

9. South Asia & Oceania Inflammatory Bowel Disease Market Outlook: Historical (2019-2023) and Forecast (2024-2031)

• 9.1. Key Highlights
• 9.2. Pricing Analysis
• 9.3. Historical Market Size (US$ Bn) Analysis, By Market, 2019-2023
  • 9.3.1. By Country
  • 9.3.2. By Disease Type
  • 9.3.3. By Drug Class
  • 9.3.4. By Distribution Channel
• 9.4. Current Market Size (US$ Bn) Analysis and Forecast, By Country, 2024-2031
  • 9.4.1. India
  • 9.4.2. Southeast Asia
  • 9.4.3. ANZ
  • 9.4.4. Rest of South Asia & Oceania
• 9.5. Current Market Size (US$ Bn) Analysis and Forecast, By Disease Type, 2024-2031
  • 9.5.1. Crohn's Disease
  • 9.5.2. Ulcerative Colitis
• 9.6. Current Market Size (US$ Bn) Analysis and Forecast, By Drug Class, 2024-2031
  • 9.6.1. Aminosalicylates
  • 9.6.2. Corticosteroids
  • 9.6.3. Immunomodulators
  • 9.6.4. Others
• 9.7. Current Market Size (US$ Bn) Analysis and Forecast, By Distribution Channel, 2024-2031
  • 9.7.1. Hospital Pharmacies
  • 9.7.2. Retail Pharmacies
  • 9.7.3. E-Commerce Platforms
  • 9.7.4. Others
• 9.8. Market Attractiveness Analysis

10. Latin America Inflammatory Bowel Disease Market Outlook: Historical (2019-2023) and Forecast (2024-2031)

• 10.1. Key Highlights
• 10.2. Pricing Analysis
• 10.3. Historical Market Size (US$ Bn) Analysis, By Market, 2019-2023
  • 10.3.1. By Country
  • 10.3.2. By Disease Type
  • 10.3.3. By Drug Class
  • 10.3.4. By Distribution Channel
• 10.4. Current Market Size (US$ Bn) Analysis and Forecast, By Country, 2024-2031
  • 10.4.1. Brazil
  • 10.4.2. Mexico
  • 10.4.3. Rest of Latin America
• 10.5. Current Market Size (US$ Bn) Analysis and Forecast, By Disease Type, 2024-2031
  • 10.5.1. Crohn's Disease
  • 10.5.2. Ulcerative Colitis
• 10.6. Current Market Size (US$ Bn) Analysis and Forecast, By Drug Class, 2024-2031
  • 10.6.1. Aminosalicylates
  • 10.6.2. Corticosteroids
  • 10.6.3. Immunomodulators
  • 10.6.4. Others
• 10.7. Current Market Size (US$ Bn) Analysis and Forecast, By Distribution Channel, 2024-2031
  • 10.7.1. Hospital Pharmacies
  • 10.7.2. Retail Pharmacies
  • 10.7.3. E-Commerce Platforms
  • 10.7.4. Others
• 10.8. Market Attractiveness Analysis

11. Middle East & Africa Inflammatory Bowel Disease Market Outlook: Historical (2019-2023) and Forecast (2024-2031)

• 11.1. Key Highlights
• 11.2. Pricing Analysis
• 11.3. Historical Market Size (US$ Bn) Analysis, By Market, 2019-2023
  • 11.3.1. By Country
  • 11.3.2. By Disease Type
  • 11.3.3. By Drug Class
  • 11.3.4. By Distribution Channel
• 11.4. Current Market Size (US$ Bn) Analysis and Forecast, By Disease Type, 2024-2031
  • 11.4.1. Crohn's Disease
  • 11.4.2. Ulcerative Colitis
• 11.5. Current Market Size (US$ Bn) Analysis and Forecast, By Drug Class, 2024-2031
  • 11.5.1. Aminosalicylates
  • 11.5.2. Corticosteroids
  • 11.5.3. Immunomodulators
  • 11.5.4. Others
• 11.6. Current Market Size (US$ Bn) Analysis and Forecast, By Distribution Channel, 2024-2031
  • 11.6.1. Hospital Pharmacies
  • 11.6.2. Retail Pharmacies
  • 11.6.3. E-Commerce Platforms
  • 11.6.4. Others
• 11.7. Market Attractiveness Analysis

12. Competition Landscape

• 12.1. Market Share Analysis, 2023
• 12.2. Market Structure
  • 12.2.1. Competition Intensity Mapping by Market
  • 12.2.2. Competition Dashboard
• 12.3. Company Profiles (Details - Overview, Financials, Strategy, Recent Developments)
  • 12.3.1. AbbVie Inc.
    • 12.3.1.1. Overview
    • 12.3.1.2. Segments and Disease Types
    • 12.3.1.3. Key Financials
    • 12.3.1.4. Market Developments
    • 12.3.1.5. Market Strategy
  • 12.3.2. Janssen Biotech, Inc.
  • 12.3.3. Pfizer Inc.
  • 12.3.4. Takeda Pharmaceutical Company Limited
  • 12.3.5. Ferring Pharmaceuticals
  • 12.3.6. Amgen Inc.
  • 12.3.7. Eli Lilly and Company
  • 12.3.8. Novartis AG
  • 12.3.9. Bristol-Myers Squibb
  • 12.3.10. Johnson & Johnson
  • 12.3.11. Merck & Co., Inc.
  • 12.3.12. GlaxoSmithKline plc

13. Appendix

• 13.1. Research Methodology
• 13.2. Research Assumptions
• 13.3. Acronyms and Abbreviations